Strategic Blueprint’s BioNTech BNTX Stock Holding History

Strategic Blueprint’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-40	Closed	-$9K	–	510
2021 Q2	$9K	Buy	+40	New	+$7.54K	﹤0.01%	977

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Strategic Blueprint's BNTX Position: Q3 2021 in Review

Strategic Blueprint sold out of BioNTech (BNTX) in Q3 2021, closing a stake of 40 shares — an estimated $9K sold.

Strategic Blueprint first reported a position in BNTX in Q2 2021 and held it in 1 quarter. The position peaked at $9K in Q2 2021. 335 funds tracked by Wall St. Rank hold BNTX as of Q3 2021.

Strategic Blueprint reported no remaining BioNTech position as of Q3 2021 after selling out during the quarter.
Strategic Blueprint sold 40 BioNTech shares in Q3 2021, an estimated $9K.
Strategic Blueprint first reported a position in BioNTech in Q2 2021 and held it in 1 quarter.
Strategic Blueprint's BioNTech position peaked at $9K in Q2 2021.
335 funds tracked by Wall St. Rank held BioNTech as of Q3 2021.

Based on Strategic Blueprint's 13F filing for Q3 2021, filed 12 Nov 2021.